[A01] Goat Anti-Human Albumin Polyclonal AntibodyAL10A-G1
|Concentration:||1 mg/ml (OD 1.35 / 280 nm)|
|Buffer:||75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2|
|Specificity||Specifically binds to human albumin. Dilution for immunoblot & ELISA range: 1,000 to 80,000. Centrifuge before use.|
|Use:||The antibody can be used for detection of human albumin in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.|
|Storage:||-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.|
*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Human albumin constitutes around 55% of the protein present in the plasma of normal healthy individuals. It is a single polypeptide chain of 585 amino acids with a molecular weight of 66 kDa.
The functions of human serum albumin include maintaining oncotic pressure; binding substances or drugs; regulating endogenous substances, metabolism; plasma buffer; antioxidant function; maintaining microvascular integrity; anticoagulant effects; inflammatory/anti-inflammatory effects; cell-signaling process. (Nicholson et al., 2000; Evans, 2002) Albumin also has functions that may play a critical role and have a great impact on different types of diseases, including hypo-albumin aemia and peripheral oedema. (Caironi et al. 2009)
Caironi, Pietro, and Luciano Gattinoni. "The clinical use of albumin: the point of view of a specialist in intensive care. " Blood Tranfusion 7.4 (2009): 259-67.
Evans, T. W. "Review Article: Albumin as a Drug-biological Effects of Albumin Unrelated to Oncotic Pressure." Alimentary Pharmacology and Therapeutics 16 (2002): 6-11.
Nicholson, J. P., M. R. Wolmarans, and G. R. Park. "The Role of Albumin in Critical Illness." British Journal of Anaesthesia 85.4 (2000): 599-610.
|[A01]||2007||Kiyota, Akifumi; Matsushita, Taku; Ueoka, Ryuichi (2007): Induction and high density culture of human hepatoblasts from fetal hepatocytes with suppressing transformation. In Biological & pharmaceutical bulletin 30 (12), pp. 2308–2311.|
|[A01]||2006||Clavant, Steven P.; Sastra, Steve A.; Osicka, Tanya M.; Comper, Wayne D. (2006): The analysis and characterisation of immuno-unreactive urinary albumin in healthy volunteers. In Clinical biochemistry 39 (2), pp. 143–151. DOI: 10.1016/j.clinbiochem.2005.10.013.|